October 14, 2026 · Decision research
Biotech Pharma Breakthroughs
Finding
Lower-cost pills appear to attract genuinely new patients, but durable paid treatment remains the missing proof for an investment decision.
What changed
The latest oral-pill study selects patients who stayed on treatment; independent evidence shows improving continuation for injections, not yet for the new pills.
Decision
Set the previously unspecified action to WATCH: do not initiate a sector-wide purchase on prescription growth alone, and do not sell existing holdings solely because prices are falling.
Watch next
Follow repeat fills at maintenance doses, actual Medicare dispensing, and recurring profitability after launch inventory and rebate adjustments.